Ramelteon for a Nap Prior to a Night Shift

Effects of Ramelteon on Sleep and Neurobehavioral Performance in a Simulated Night Shift Preceded by a Sleep Opportunity

Sponsors

Lead Sponsor: Brigham and Women's Hospital

Collaborator: Takeda

Source Brigham and Women's Hospital
Brief Summary

Night shift-workers are often advised to take a prophylactic nap prior to starting the shift in order to improve alertness and performance. However, individuals often report difficulty initiating and maintaining sleep at that time of the day secondary to the alerting influence of the near-24 hour circadian rhythm (biological clock). A sleep-promoting medication may improve the quality of an evening nap and subsequent alertness and performance during a night shift. We will use Ramelteon, a melatonin agonist that is FDA approved for insomnia, in order to test the following hypotheses:

1. ramelteon, compared with placebo, will significantly increase sleep efficiency during a 2-hour nap;

2. sleep inertia, as assessed by neurobehavioral tests and subjective and objective sleepiness assessments will not be significantly increased after ramelteon treatment compared with placebo treatment; and

3. neurobehavioral performance, subjective and objective sleepiness, and subjective mood during a simulated 8-hour night shift will be significantly improved when ramelteon is given prior to a prophylactic nap compared to a prophylactic nap with placebo.

Overall Status Completed
Start Date December 2007
Completion Date November 2008
Primary Completion Date November 2008
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Sleep Efficiency 2 hours
Enrollment 11
Condition
Intervention

Intervention Type: Drug

Intervention Name: Ramelteon

Description: Ramelteon 8 mg tablet by mouth x 1 dose

Arm Group Label: 1

Other Name: Rozerem

Intervention Type: Drug

Intervention Name: placebo

Description: placebo identical in appearance to active experimental drug x 1 dose

Arm Group Label: 2

Eligibility

Criteria:

Inclusion Criteria:

- Aged between 18-35 years;

- Non-smoking for at least 6 months;

- Healthy (no medical, psychiatric or sleep disorders);

- No clinically significant deviations from normal in medical history, vital signs, physical examination, blood chemistry and hematology, and ECG;

- Women of childbearing potential must agree to use an acceptable method of birth control, and must have a negative serum pregnancy test;

- Body mass index of > 18 or < 30 kg/m∧2;

- No drugs or medication likely to affect sleep or alertness, as determined by the investigators;

- Habitual caffeine consumption < 300 mg per day on average;

- Habitual alcohol consumption < 10 alcoholic units per week on average.

Exclusion Criteria:

- History of alcohol or substance abuse;

- Positive result on drugs of abuse screening;

- Current or past history of sleep disorders, including but not limited to obstructive sleep apnea, or any significant sleep complaint;

- Psychiatric disorder, including a history of depression or dysthymia (characterized by depressed mood on the majority of days for at least two years);

- Recent acute or chronic medical disorder, including but not limited to hepatic impairment and severe chronic obstructive pulmonary disease;

- History of intolerance or hypersensitivity to melatonin or melatonin agonists;

- Pregnancy or lactation;

- Shift work;

- Transmeridian travel (2 or more time zones) in past 2 months;

- Any other scientific or medical reason, as determined by the PI, such as non-compliance with protocol or intolerance to inpatient study conditions.

Gender: All

Minimum Age: 18 Years

Maximum Age: 35 Years

Healthy Volunteers: Accepts Healthy Volunteers

Overall Official
Verification Date

October 2012

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Brigham and Women's Hospital

Investigator Full Name: Elizabeth B. Klerman

Investigator Title: Associate Professor, Associate Physician

Keywords
Has Expanded Access No
Number Of Arms 2
Arm Group

Label: 1

Type: Experimental

Description: Ramelteon 8 mg will be given once prior to a 2-hour nap

Label: 2

Type: Placebo Comparator

Description: Placebo will be given once prior to a 2-hour nap

Study Design Info

Allocation: Randomized

Intervention Model: Crossover Assignment

Primary Purpose: Basic Science

Masking: Triple (Participant, Investigator, Outcomes Assessor)

Source: ClinicalTrials.gov